Get the Stockscreener App
5.35
6.57%
0.33
After Hours:
5.30
-0.05
-0.93%
Verrica Pharmaceuticals Inc stock is traded at $5.35, with a volume of 102.11K.
It is up +6.57% in the last 24 hours and down -21.78% over the past month.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
See More
Previous Close:
$5.02
Open:
$5.08
24h Volume:
102.11K
Relative Volume:
1.84
Market Cap:
$91.91M
Revenue:
$37.16M
Net Income/Loss:
$-17.83M
P/E Ratio:
-5.1741
EPS:
-1.034
Net Cash Flow:
$-14.22M
1W Performance:
-2.55%
1M Performance:
-21.78%
6M Performance:
-26.81%
1Y Performance:
-19.06%
1-Day Range:
$5.00
$5.44
1-Week Range:
$5.00
$5.74
52-Week Range:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Name
Verrica Pharmaceuticals Inc
Sector
Industry
Phone
484-453-3300
Address
44 WEST GAY STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
5.35 | 86.24M | 37.16M | -17.83M | -14.22M | -1.034 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-25-23 | Upgrade | Needham | Hold → Buy |
| Mar-22-23 | Initiated | Jefferies | Buy |
| Feb-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-25-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-20 | Initiated | Northland Capital | Outperform |
| Mar-24-20 | Initiated | Needham | Buy |
| Feb-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Verrica Pharmaceuticals Inc Stock (VRCA) Latest News
Verrica Pharmaceuticals Inc (VRCA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VRCA|Verrica Pharmaceuticals Inc|Price:5.020|Chg%:-0.420 - TradingKey
TradingKey - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Verrica Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:VRCA - TradingView
Verrica Pharmaceuticals Inc (VRCA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Verrica grants Medomie exclusive rights for YCANTH in Israel By Investing.com - Investing.com Nigeria
Verrica grants Medomie exclusive rights for YCANTH in Israel - Investing.com
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel - The Manila Times
Verrica deal could bring YCANTH to Israeli children if approved - Stock Titan
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISI - GuruFocus
Verrica Pharmaceuticals (VRCA) Slides 4.13% as Resistance Holds FirmForce Index - dars.gov.et
Verrica Pharmaceuticals holds the spotlight after recent market context - ad-hoc-news.de
Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
VRCAVerrica Pharmaceuticals Inc Latest SEC Filings - Finviz
VRCA News | VERRICA PHARMACEUTICALS INC (NASDAQ:VRCA) - ChartMill
Verrica Pharmaceuticals (VRCA) Rises 2% as Shares Test Resistance Near $6.36Sentiment Shift - dars.gov.et
Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell 3000E Growth Benchmark - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM: VRCA) added to Russell 3000E Index - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM: VRCA) added to Russell Microcap Index - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Number of shareholders of Verrica Pharmaceuticals Inc. – DUS:1NE0 - TradingView
Enterprise value to EBITDA forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Price to book forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Verrica Pharmaceuticals Inc. Cash Flow – DUS:1NE0 - TradingView
Price to sales forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. – DUS:1NE0 - TradingView
Price to earnings ratio of Verrica Pharmaceuticals Inc. – DUS:1NE0 - TradingView
Verrica Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:VRCA) - TradingView
VRCA Forecast — Price Target — Prediction for 2027 - TradingView
Verrica Pharmaceuticals Inc. Actuals & Estimates (SWB:1NE0) - TradingView
1NE0 Forecast — Price Target — Prediction for 2027 - TradingView
A41A98 Forecast — Price Target — Prediction for 2027 - TradingView
Verrica Advances Wart Treatment Program With Phase 3 Trial Expansion - MyChesCo
Verrica Pharmaceuticals (VRCA) Surges 6%: Momentum Builds Above Key SupportCash Flow Strong Stocks - dars.gov.et
Verrica Pharmaceuticals Inc (VRCA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
H.C. Wainwright reiterates Verrica stock rating on trial progress - Investing.com UK
Milestone Alert: First US Patient Dosed in the Second Phase 3 Trial of Verrica’s YCANTH for Common Warts - The Dermatology Digest
H.C. Wainwright reiterates Verrica stock rating on trial progress By Investing.com - Investing.com Australia
H.C. Wainwright Maintains Verrica Pharmaceuticals(VRCA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Verrica doses first U.S. patient in common warts trial By Investing.com - Investing.com South Africa
Verrica doses first U.S. patient in common warts trial - Investing.com
Verrica starts Phase 3 common-warts trial with first U.S. patient - Stock Titan
Verrica doses first U.S. patient in Phase 3 tri... - Pluang
Verrica Pharmaceuticals Inc (VRCA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Institutional Confidence - TradingKey
Verrica Pharmaceuticals (VRCA) Holds Steady Near $6.0, Eyeing Resistance at $6.3Put Dominated - newsline.com
Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):